Oestrogens, oestrogen receptors and breast cancer

European Journal of Cancer, Supplement

Volumn 1, Issue 1, 2003, Pages 1-12

  Bentrem, D J ^a   Gaiha, P ^a   Jordan, V C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Anastrozole; Anti oestrogens; Breast cancer; Drug resistance; Raloxifene; Tamoxifen

Indexed keywords

ANASTROZOLE; ANDROSTENEDIONE; AROMATASE INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TESTOSTERONE;

ADULT; ARTICLE; BLOOD CLOTTING DISORDER; BODY FAT; BONE DENSITY; BREAST CARCINOMA; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 2442534270     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(03)00002-8     Document Type: Article

References (118)

1. Byers T., Mouchawar J., Marks J., et al. The American Cancer Society challenge goals. How far can cancer rates decline in the U.S. by the year 2015? Cancer. 86:1999;715-727
2. Baumler E., Ehrlich P. Scientist for Life. 1984;Holmes & Meier, New York
3. Lacassagne A. Hormonal pathogenesis of adenocarcinoma of the breast. Am J Cancer. 27:1936;217-225
4. Lerner L.J., Holthaus J.F., Thompson C.R. A non-steroidal estrogen antagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenylethanol. Endocrinology. 63:1958;295-318
5. Lerner L.J. The first non-steroidal antiestrogen-MER 25. Sutherland R.L., Jordan V.C. Nonsteroidal Antioestrogens: Molecular Pharmacology and Antitumour Activity. 1981;1-6 Sydney, Australia, Sydney Academic Press
6. Lerner L.J., Jordan V.C. The development of antiestrogens for the treatment of breast cancer. Eighth Cain Memorial Award Lecture Cancer Res. 50:1990;4177-4189
7. Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2:2003;205-213
8. Jensen E.V., Jacobson H.I. Basic guides to the mechanism of estrogen action. Recent Prog Horm Res. 18:1962;387-414
9. Greene G., Fitch F.W., Jensen E.V. Monoclonal antibodies to estrophilin. probes for the study of estrogen receptors Proc Natl Acad Sci USA. 77:1980;157-161
10. Greene G.L., Gilna P., Waterfield M., et al. Sequence and expression of human estrogen receptor complementary DNA. Science. 231:1986;1150-1154
11. King W.J., Green G.L. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature. 307:1984;745-747
12. McGuire W.L., Horwitz K.B., Zava D.T., et al. Hormones in breast cancer: update 1978. Metabolism. 27:1978;487-501
13. Thorpe S.M., Rose C., Rasmussen B.B., et al. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res. 47:1987;6126-6133
14. Jensen E.V., Block G.E., Smith S., et al. Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Monogr. 34:1971;55-70
15. McGuire W.L., Carbone P.P., Vollmer E.P. Estrogen Receptors in Human Breast Cancer. 1975;Raven Press, New York
16. EBCTCG Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 351:1998;1451-1467
17. Jordan V.C. The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole. Breast Cancer Res Treat. 11:1988;197-209
18. Jordan V.C. Designer estrogens. Sci Am. 279:1998;60-67
19. Jordan V.C. Selective estrogen receptor modulation. a personal perspective Cancer Res. 61:2001;5683-5687
20. Furr B.J., Jordan V.C. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther. 25:1984;127-205
21. Jordan V.C., Koerner S. Tamoxifen (ICI 46, 474) and the human carcinoma 8S oestrogen receptor. Eur J Cancer. 11:1975;205-206
22. MacGregor Schafer J.I., Jordan V.C. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev. 50:1998;151-196
23. Green S., Walter P., Kumar V., et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature. 320:1986;134-139
24. Kuiper G.G., Enmark E., Pelto-Huikko M., et al. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA. 93:1996;5925-5930
25. Mosselman S., Polman J., Dijkema R. ER beta. identification and characterization of a novel human estrogen receptor FEBS Lett. 392:1996;49-53
26. Enmark E., Pelto-Huikko M., Grandien K., et al. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab. 82:1997;4258-4265
27. Couse J.F., Curtis S.W., Washburn T.F., et al. Analysis of transcription and estrogen insensitivity in the female mouse after targeted disruption of the estrogen receptor gene. Mol Endocrinol. 9:1995;1441-1454
28. Stewart P.J., Stern P.H. Effects of the anitestrogens tamoxifen and clomiphene on bone resportion in vitro. Endocrinology. 118:1986;125-131
29. Jordan V.C., Phelps E., Lindgren J.U. Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat. 10:1987;31-35
30. Love R.R., Mazess R.B., Barden H.S., et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer [see comments]. N Engl J Med. 326:1992;852-856
31. Kedar R.P., Bourne T.H., Powles T.J., et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial [see comments]. Lancet. 343:1994;1318-1321
32. Jordan V.C., Fritz N.F., Tormey D.C. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res. 47:1987;624-630
33. Kristensen B., Ejlertsen B., Dalgaard P., et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol. 12:1994;992-997
34. Rossner S., Wallgren A. Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis. 86:1984;1534-1539
35. Love R.R., Wiebe D.A., Newcomb P.A., et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med. 115:1991;860-864
36. Love R.R., Wiebe D.A., Feyzi J.M., et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst. 86:1994;1534-1539
37. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women principal results from the women's health initiative randomized controlled trial. JAMA. 288:2002;321-333
38. Assikis V.J., Jordan V.C. Gynecologic effects of tamoxifen and the association with endometrial carcinoma. Int J Gynaecol Obstet. 49:1995;241-257
39. Goldstein S.R. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen [see comments]. Am J Obstet Gynecol. 170:1994;447-451
40. Descensi A., Fontana V., Bruno S., et al. Effect of tamoxifen on enodmetrial proliferation. J Clin Oncol. 14:1996;434-440
41. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 90:1998;1371-1388
42. Fisher B., Costantino J.P., Redmond C.K., et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 86:1994;527-537
43. Gottardis M.M., Jordan V.C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res. 48:1988;5183-5187
44. Howell A., Dodwell D.J., Anderson H., et al. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer [see comments]. Ann Oncol. 3:1992;611-617
45. Shang Y., Brown M. Molecular determinants for the tissue specificity of SERMs. Science. 295:2002;2465-2468
46. Font de Mora J., Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Molecular and Cellular Biology. 20:2000;5041-5047
47. Newman S.P., Bates N.P., Vernimmen D., et al. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene. 19:2000;490-497
48. Wijayaratne A.L., McDonnell D.P. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem. 276:2001;35684-35692
49. Pearce ST, Liu H, Jordan VC Modulation of ER function and stability by tamoxifen and a critical amino acid D538 in helix 12. J Biol Chem. 278:2003;7630-7638
50. List H.-J., Lauritsen K.J., Reiter R., et al. Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. J Biol Chem. 276:2001;23763-23768
51. Lauritsen K.J., List H.-J., Reiter R., et al. A role for TGF-beta in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells. Oncogene. 21:2002;7147-7155
52. Osborne CK, Bardou V, Hopp TA, et al. Estrogen receptor coactivator AIB1 (SRC3) is required with HER2/neu for the tamoxifen resistance in breast cancer. JNCI. 95:2003;353-361
53. Wakeling A.E., Dukes M., Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 51:1991;3867-3873
54. Dauvois S., Danielian P.S., White R., et al. Antiestrogen ICI 164, 384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA. 89:1992;4037-4041
55. Gibson M.K., Nemmers L.A., Beckman W.C. Jr., et al. The mechanism of ICI 164, 384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology. 129:1991;2000-2010
56. Gottardis M.M., Jiang S.Y., Jeng M.H., et al. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res. 49:1989;4090-4093
57. Osborne C.K., Coronado-Heinsohn E.B., Hilsenbeck S.G., et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst. 87:1995;746-750
58. Gottardis M.M., Ricchio M.E., Satyaswaroop P.G., et al. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Res. 50:1990;3189-3192
59. O'Regan R.M., Cisneros A., England G.M., et al. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182, 780 on endometrial cancer growth [see comments]. J Natl Cancer Inst. 90:1998;1552-1558
60. Howell A., Osborne C.K., Morris C., et al. ICI 182, 780 (Faslodex): development of a novel. "pure" antiestrogen. Cancer. 89:2000;817-825
61. Howell A., Robertson J.F.R., Quaresma Albano J., et al. Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 20:2002;3396-3403
62. Osborne C.K., Pippen J., Jones S.E., et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 20:2002;3386-3395
63. Simpson E.R., Zhao Y., Agarwal V.R., et al. Aromatase expression in health and disease. Recent Prog Horm Res. 52:1997;185-213
64. Santen R.J., Santner S.J., Pauley R.J., et al. Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible? J Steroid Biochem Mol Biol. 61:1997;267-271
65. de Jong, PC, de Ven, JV, Nortier, JWR, et al. Inhibition of intratumoural aromatase activity and estradiol by exemestane in postmenopausal breast cancer patients: results of a double blind randomised study. In Proceedings of ASCO, 2001; San Francisco, 2001, 130.
66. Goss P.E., Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol. 19:2001;881-894
67. Kvinnsland S., Anker G., Dirix L.Y., et al. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment. Eur J Cancer. 36:2000;976-982
68. Kaufmann M., Bajetta E., Dirix L.Y., et al. Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results of a double-blind randomised phase III trial. Eur J Cancer. 36(Suppl 4):2000;S86-S87
69. Buzdar A. Exemestane in advanced breast cancer. Anticancer Drugs. 11:2000;609-616
70. Nabholtz J.M. Steroidal side effects of exemestane. J Clin Oncol. 19:2001;2107-2108
71. Nabholtz J.M., Buzdar A., Pollak M., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 18:2000;3758-3767
72. Bonneterre J., Thurlimann B., Robertson J.F., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol. 18:2000;3748-3757
73. Donnellan P.P., Douglas S.L., Cameron D.A., et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 19:2001;2767
74. Dombernowsky P., Smith I., Falkson G., et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 16:1998;453-461
75. Buzdar A., Douma J., Davidson N., et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol. 19:2001;3357-3366
76. Mouridsen H., Gershanovich M., Sun Y., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 19:2001;2596-2606
77. Dixon J.M., Love C.D.B., Bellamy C., et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat. 66:2001;191-199
78. Lohrisch, C, Paridaens, R, Dirix, Y, et al. No adverse impact on serum lipids of the irreversible aromatase inactivator aromasin in 1st line treatment of metastatic breast cancer: companion study to a european organization of research and treatment of cancer trial with Pharmacias' Upjohn. In ASCO 2001, 12 May, San Francisco, CA, 2001, 167.
79. The ATAC Trialist Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet. 359:2002;2131-2139
80. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy then tamoxifen for ErbB-1 and/or ErbB-2 positive estrogen receptor positive primary breast cancer: evidence from a phase III study. J Clin Oncol. 19:2001;3808-3816
81. Jordan V.C. Effect of tamoxifen (ICI 46, 474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer. 12:1976;419-424
82. Jordan V.C., Allen K.E. Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer. 16:1980;239-251
83. Powles T., Eeles R., Ashley S., et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial [see comments]. Lancet. 352:1998;98-101
84. Veronesi U., Maisonneuve P., Costa A., et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet. 352:1998;93-97
85. Decensi A., Bonanni B., Rotmensz N., et al. Update on tamoxifen to prevent breast cancer. The Italian Tamoxifen Prevention Study. Eur J Cancer. 36(Suppl 4):2000;S50-S51
86. Veronesi U., Maisonneuve P., Rotmensz N., et al. Italian randomized trail among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. JNCI. 95:2003;160-165
87. IBIS Investigators First results from the International Breast Study: a randomized prevention trial. Lancet. 360:2002;817-824
88. King M.C., Wieand S., Hale K., et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. Jama. 286:2001;2251-2256
89. Narod S.A., Brunet J.-S., Ghadirian P., et al. Tamoxifen and risk of contralateral breast cancer in BRCA 1 BRCA 2 mutation carriers. Lancet. 356:2000;1876-1886
90. Gail M.H., Brinton L.A., Byar D.P., et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually [see comments]. J Natl Cancer Inst. 81:1989;1879-1886
91. Costantino J.P., Gail M.H., Pee D., et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 91:1999;1541-1548
92. Jones C.D., Jevnikar M.G., Pike A.J., et al. Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J Med Chem. 27:1984;1057-1066
93. Black L.J., Jones C.D., Falcone J.F. Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci. 32:1983;1031-1036
94. Lerner L.J., Jordan V.C. Development of antiestrogens and their use in breast cancer. eighth Cain memorial award lecture Cancer Res. 50:1990;4177-4189
95. Gottardis M.M., Jordan V.C. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res. 47:1987;4020-4024
96. Anzano M.A., Peer C.W., Smith J.M., et al. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst. 88:1996;123-125
97. Snyder K.R., Sparano N., Malinowski J.M. Raloxifene hydrochloride. Am J Health Syst Pharm. 57:2000;1669-1675. [quiz 1676-1678]
98. Black L.J., Sato M., Rowley E.R., et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest. 93:1994;63-69
99. Sato M., McClintock C., Kim J., et al. Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats. J Bone Miner Res. 9:1994;715-724
100. Turner C.H., Sato M., Bryant H.U. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology. 135:1994;2001-2005
101. Sato M.K.J., Short L.L., Slemenda C.W., Bryant H.U. Longitudinal and corss sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. J Pharmacol Exp Ther. 272:1995;1252-1259
102. Frolik C.A., Bryant H.U., Black E.C., et al. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate. Bone. 18:1996;621-627
103. Sato M., Rippy M.K., Bryant H.U. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. Faseb J. 10:1996;905-912
104. Delmas P.D., Bjarnason N.H., Mitlak B.H., et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women [see comments]. N Engl J Med. 337:1997;1641-1647
105. Walsh B.W., Kuller L.H., Wild R.A., et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 279:1998;1445-1451
106. Walsh B.W., Paul S., Wild R.A., et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 85:2000;214-218
107. Bjarnason N.H., Haarbo J., Byrjalsen I., et al. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation. 96:1997;1964-1969
108. Clarkson T.B., Anthony M.S., Jerome C.P. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab. 83:1998;721-726
109. Jordan V.C., Gapstur S., Morrow M. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst. 93:2001;1449-1457
110. Cauley J.A., Norton L., Lippman M.E., Eckert S., Krueger K.A., Purdie D.W., Farrerons J., Karasik A., Mellstrom D., Ng K.W., Stephan J.J., Powles T.J., Morrow M., Costa A., Silfen S.L., Walls E.L., Schmitt H., Muchmore D.B., Jordan V.C. Continued breast cancer rusk reduction in postmenopausal women treated with raloxifene. 4-year results from the MORE trial Breast Cancer Res Treat. 65:2001;125-134
111. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 280:1998;605-613
112. Boss S.M., Huster W.J., Neild J.A., et al. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol. 177:1997;1458-1464
113. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [see comments]. JAMA. 282:1999;637-645
114. Cummings S.R., Eckert S., Krueger K.A., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 281:1999;2189-2197
115. Lippman M.E., Krueger K.A., Eckert S., et al. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. J Clin Oncol. 19:2001;3111-3116
116. Lonning P.E., Taylor P.D., Anker G., et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat. 67:2001;111-116
117. Yao K., Lee E.S., Bentrem D.J., et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice [in process citation]. Clin Cancer Res. 6:2000;2028-2036
118. Song R.X., Mor G., Naftolin F., et al. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst. 93:2001;1714-1723